Pages that link to "Q33449885"
Jump to navigation
Jump to search
The following pages link to Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders (Q33449885):
Displaying 50 items.
- Gut Microbiota Modification: Another Piece in the Puzzle of the Benefits of Physical Exercise in Health? (Q26765902) (← links)
- Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis (Q28244815) (← links)
- A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life (Q33455506) (← links)
- A pilot study on the effect of a symbiotic mixture in irritable bowel syndrome: an open-label, partially controlled, 6-month extension of a previously published trial (Q33458837) (← links)
- Lactobacillus acidophilus supplementation in human subjects and their resistance to enterotoxigenic Escherichia coli infection. (Q33458873) (← links)
- Impact of genomics on the field of probiotic research: historical perspectives to modern paradigms (Q33780331) (← links)
- Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1. (Q33908943) (← links)
- Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome (Q33954221) (← links)
- Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health (Q34332869) (← links)
- Bloating and functional gastro-intestinal disorders: where are we and where are we going? (Q34366956) (← links)
- Transcriptional analysis of prebiotic uptake and catabolism by Lactobacillus acidophilus NCFM. (Q34427074) (← links)
- The effect of selected synbiotics on microbial composition and short-chain fatty acid production in a model system of the human colon (Q34452017) (← links)
- Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study (Q35056944) (← links)
- Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis (Q35375748) (← links)
- Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. (Q35586987) (← links)
- Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air? (Q35691226) (← links)
- Probiotic and anti-inflammatory attributes of an isolate Lactobacillus helveticus NS8 from Mongolian fermented koumiss (Q35795912) (← links)
- Molecular characterization of the intestinal microbiota in patients with and without abdominal bloating (Q35878015) (← links)
- Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis (Q36050769) (← links)
- Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study (Q36185519) (← links)
- Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It? (Q36211712) (← links)
- Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (Q36310200) (← links)
- S-layer protein mediates the stimulatory effect of Lactobacillus helveticus MIMLh5 on innate immunity. (Q36599131) (← links)
- Oral administration of fermented milk supplemented with synbiotics can influence the physiological condition of Wistar rats in a dose-sensitive and sex-specific manner (Q36875924) (← links)
- Short term (14 days) consumption of insoluble wheat bran fibre-containing breakfast cereals improves subjective digestive feelings, general wellbeing and bowel function in a dose dependent manner (Q36994108) (← links)
- Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (Q37234770) (← links)
- Modulation of anti-inflammatory response in lipopolysaccharide stimulated human THP-1 cell line and mouse model at gene expression level with indigenous putative probiotic lactobacilli (Q37299999) (← links)
- Irritable bowel syndrome symptom severity improves equally with probiotic and placebo (Q37538949) (← links)
- Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis. (Q37677017) (← links)
- Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria. (Q37973803) (← links)
- Intestinal microbiota, pathophysiology and translation to probiotic use in patients with irritable bowel syndrome. (Q38014500) (← links)
- Probiotics use to treat irritable bowel syndrome (Q38035021) (← links)
- Complementary and alternative medicine and mind-body therapies for treatment of irritable bowel syndrome in women (Q38155671) (← links)
- American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation (Q38236812) (← links)
- Probiotic Formulations: Application and Status as Pharmaceuticals-A Review (Q38702214) (← links)
- An Extracellular Cell-Attached Pullulanase Confers Branched α-Glucan Utilization in Human Gut Lactobacillus acidophilus (Q38836154) (← links)
- Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. (Q39172677) (← links)
- Complete genome sequences of probiotic strains Bifidobacterium animalis subsp. lactis B420 and Bi-07. (Q42131498) (← links)
- A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms (Q46116511) (← links)
- Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome (Q46302916) (← links)
- Effects of probiotic supplementation over 5 months on routine haematology and clinical chemistry measures in healthy active adults (Q46317211) (← links)
- Close association between intestinal microbiota and irritable bowel syndrome (Q46324386) (← links)
- The life history of Lactobacillus acidophilus as a probiotic: a tale of revisionary taxonomy, misidentification and commercial success (Q46979248) (← links)
- Probiotics or Pro-healers the Role of Beneficial Bacteria in Tissue Repair (Q47189424) (← links)
- A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). (Q49721831) (← links)
- Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. (Q52672657) (← links)
- Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. (Q55312184) (← links)
- Transcriptional and functional analysis of subsp. exposure to tetracycline (Q57147153) (← links)
- Differential expression of tumor-associated genes and altered gut microbiome with decreased Akkermansia muciniphila confer a tumor-preventive microenvironment in intestinal epithelial Pten-deficient mice (Q57186040) (← links)
- Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2 (Q58610324) (← links)